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background: The clinical implications of non-sustained ventricular tachycardia (NSVT) during the recovery phase following ACS with regard to 
cardiovascular outcomes are not well-described.
methods: The PLATO continuous ECG (cECG) substudy included 1,991 patients with repeat cECG recording lasting up to 7 days performed 
beginning Day-30 after the ACS event. Median follow-up was 1 year. NSVT was defined as >=4 consecutive beats >100 bpm. Risk was adjusted for 
TIMI risk score, prior MI, prior HF, CrCl and revascularization during index hospitalization.
results: The median duration of cECG monitoring was 6.8 days. A total of 428 pts (21.5%) experienced >=1 episode of NSVT on the cECG 
recording beginning at Day 30, more commonly in patients with STEMI (24.7%) vs. NSTEACS (20.6%). Overall, NSVT at 30 days was significantly 
associated with an increased risk of CV death, though the relative risk changed over time. The highest risk of CV death was observed within ~5 
months after ACS, whereas the risk after that time was not increased. (Figure)
conclusion: A 7-day cECG recording detected NSVT in approximately 25%/21% of STEMI/NSTEACS patients 30 days following ACS and was 
significantly associated with an increased risk of CV death, in particular during the subsequent 4 months. These novel observations in a broad ACS 
population provide relevant clinical data when considering the appropriate therapies and strategies to identify vulnerable individuals with persistent 
substrate for ventricular arrhythmia following ACS.
